NR 566 Advanced Pharmacology
Final Examination Questions & Answers
Chamberlain University | 2026/2027
250 Questions with Expert Rationales
Instructions
• This examination consists of 250 multiple-choice questions.
• Select the single best answer for each question.
• Rationales provide evidence-based explanations for each correct answer.
Section 1: Pharmacokinetics, Pharmacodynamics, and
Foundational Principles (Questions 1-25)
1. An 82-year-old patient with heart failure, chronic kidney disease stage 3, and
hypoalbuminemia is prescribed a highly protein-bound medication. The NP
anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) drug. Combined with age-related renal decline (CKD stage 3),
this significantly increases the risk of toxicity. Older adults also have reduced renal
clearance, further compounding the risk.
,2. A drug has a half-life of 48 hours. Approximately how many days will it take
to reach steady state?
A. 2-3 days
B. 5-7 days
C. 8-10 days
D. 10-14 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 48-hour (2-
day) half-life, steady state occurs in approximately 8-10 days. This principle is critical
for drugs with long half-lives such as amiodarone and fluoxetine.
3. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly or allosterically, reducing the maximal response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Answer: B
Expert Rationale: A non-competitive antagonist binds irreversibly or to an
allosteric site, reducing the maximal response (efficacy) of the agonist. Unlike
competitive antagonists, its effects cannot be overcome by increasing agonist
concentration.
4. A patient is a CYP2C19 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated
conversion to its active metabolite. Poor metabolizers have reduced activation,
increasing the risk of thrombotic events, particularly after coronary stent placement.
Alternative antiplatelet agents such as ticagrelor may be considered.
5. The NP prescribes a medication with extensive first-pass metabolism. Which
route would achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intravenous
D. Subcutaneous
,Answer: C
Expert Rationale: Intravenous administration delivers the drug directly into
systemic circulation, completely bypassing first-pass metabolism and achieving 100%
bioavailability. Sublingual and buccal routes also bypass first-pass metabolism but
have variable absorption.
6. A patient with an eGFR of 18 mL/min requires a medication that is 85%
renally excreted. What is the most appropriate adjustment?
A. Increase the dose
B. Decrease the dose and/or prolong the dosing interval
C. No adjustment needed
D. Administer with a high-fat meal
Answer: B
Expert Rationale: Renally excreted drugs accumulate in severe renal impairment
(eGFR < 30 mL/min). Dose reduction or interval prolongation is required to prevent
toxicity. Drug levels should be monitored when available.
7. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Answer: A
Expert Rationale: HLA-B*5701 screening is mandatory before abacavir initiation.
Patients positive for this allele are at high risk for hypersensitivity, which can be fatal.
Screening has significantly reduced the incidence of this reaction.
8. A patient develops Stevens-Johnson syndrome after starting lamotrigine.
This is classified as which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Stevens-Johnson syndrome is a Type B (bizarre, idiosyncratic)
reaction that is unpredictable, not dose-related, and often immune-mediated.
Lamotrigine carries a black box warning for serious skin rashes, especially with rapid
dose titration.
, 9. A drug that is a P-glycoprotein (P-gp) substrate is administered orally. What
effect would a P-gp inhibitor have on this drug?
A. Decreased absorption
B. Increased absorption and increased drug levels
C. No effect
D. Increased metabolism
Answer: B
Expert Rationale: P-gp is an efflux transporter that pumps drugs back into the
intestinal lumen. P-gp inhibitors (e.g., verapamil, cyclosporine, amiodarone) increase
absorption and bioavailability, potentially leading to increased drug levels and
toxicity.
10. Which drug property most facilitates penetration across the blood-brain
barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: The blood-brain barrier consists of tight junctions between
endothelial cells. Lipophilic, non-polar, low molecular weight drugs can diffuse across
cell membranes more readily than hydrophilic or large molecules.
11. A patient is started on a medication that is a strong CYP3A4 inhibitor. The
NP anticipates that levels of CYP3A4 substrates will:
A. Decrease
B. Increase
C. Remain unchanged
D. Fluctuate unpredictably
Answer: B
Expert Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin,
grapefruit juice, ritonavir) decrease metabolism of CYP3A4 substrates, leading to
increased drug levels and potential toxicity. This is a common and significant drug
interaction.
12. Which physiologic change in older adults most significantly affects drug
absorption?
A. Decreased gastric acid secretion
B. Increased gastric emptying
C. Increased intestinal blood flow
D. Decreased intestinal surface area
Final Examination Questions & Answers
Chamberlain University | 2026/2027
250 Questions with Expert Rationales
Instructions
• This examination consists of 250 multiple-choice questions.
• Select the single best answer for each question.
• Rationales provide evidence-based explanations for each correct answer.
Section 1: Pharmacokinetics, Pharmacodynamics, and
Foundational Principles (Questions 1-25)
1. An 82-year-old patient with heart failure, chronic kidney disease stage 3, and
hypoalbuminemia is prescribed a highly protein-bound medication. The NP
anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) drug. Combined with age-related renal decline (CKD stage 3),
this significantly increases the risk of toxicity. Older adults also have reduced renal
clearance, further compounding the risk.
,2. A drug has a half-life of 48 hours. Approximately how many days will it take
to reach steady state?
A. 2-3 days
B. 5-7 days
C. 8-10 days
D. 10-14 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 48-hour (2-
day) half-life, steady state occurs in approximately 8-10 days. This principle is critical
for drugs with long half-lives such as amiodarone and fluoxetine.
3. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly or allosterically, reducing the maximal response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Answer: B
Expert Rationale: A non-competitive antagonist binds irreversibly or to an
allosteric site, reducing the maximal response (efficacy) of the agonist. Unlike
competitive antagonists, its effects cannot be overcome by increasing agonist
concentration.
4. A patient is a CYP2C19 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated
conversion to its active metabolite. Poor metabolizers have reduced activation,
increasing the risk of thrombotic events, particularly after coronary stent placement.
Alternative antiplatelet agents such as ticagrelor may be considered.
5. The NP prescribes a medication with extensive first-pass metabolism. Which
route would achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intravenous
D. Subcutaneous
,Answer: C
Expert Rationale: Intravenous administration delivers the drug directly into
systemic circulation, completely bypassing first-pass metabolism and achieving 100%
bioavailability. Sublingual and buccal routes also bypass first-pass metabolism but
have variable absorption.
6. A patient with an eGFR of 18 mL/min requires a medication that is 85%
renally excreted. What is the most appropriate adjustment?
A. Increase the dose
B. Decrease the dose and/or prolong the dosing interval
C. No adjustment needed
D. Administer with a high-fat meal
Answer: B
Expert Rationale: Renally excreted drugs accumulate in severe renal impairment
(eGFR < 30 mL/min). Dose reduction or interval prolongation is required to prevent
toxicity. Drug levels should be monitored when available.
7. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Answer: A
Expert Rationale: HLA-B*5701 screening is mandatory before abacavir initiation.
Patients positive for this allele are at high risk for hypersensitivity, which can be fatal.
Screening has significantly reduced the incidence of this reaction.
8. A patient develops Stevens-Johnson syndrome after starting lamotrigine.
This is classified as which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Stevens-Johnson syndrome is a Type B (bizarre, idiosyncratic)
reaction that is unpredictable, not dose-related, and often immune-mediated.
Lamotrigine carries a black box warning for serious skin rashes, especially with rapid
dose titration.
, 9. A drug that is a P-glycoprotein (P-gp) substrate is administered orally. What
effect would a P-gp inhibitor have on this drug?
A. Decreased absorption
B. Increased absorption and increased drug levels
C. No effect
D. Increased metabolism
Answer: B
Expert Rationale: P-gp is an efflux transporter that pumps drugs back into the
intestinal lumen. P-gp inhibitors (e.g., verapamil, cyclosporine, amiodarone) increase
absorption and bioavailability, potentially leading to increased drug levels and
toxicity.
10. Which drug property most facilitates penetration across the blood-brain
barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: The blood-brain barrier consists of tight junctions between
endothelial cells. Lipophilic, non-polar, low molecular weight drugs can diffuse across
cell membranes more readily than hydrophilic or large molecules.
11. A patient is started on a medication that is a strong CYP3A4 inhibitor. The
NP anticipates that levels of CYP3A4 substrates will:
A. Decrease
B. Increase
C. Remain unchanged
D. Fluctuate unpredictably
Answer: B
Expert Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin,
grapefruit juice, ritonavir) decrease metabolism of CYP3A4 substrates, leading to
increased drug levels and potential toxicity. This is a common and significant drug
interaction.
12. Which physiologic change in older adults most significantly affects drug
absorption?
A. Decreased gastric acid secretion
B. Increased gastric emptying
C. Increased intestinal blood flow
D. Decreased intestinal surface area
